INTRODUCTION
Type 2 diabetes is a progressive disease that requires ongoing treatment intensification to achieve and maintain glycemic control.
1 Only 53% of people with diabetes in the USA between 2007 and 2010 had the American Diabetes Association's recommended glycated hemoglobin (HbA1c) levels of less than 7%. 2 3 Studies suggest that approximately 50-60% of patients with HbA1c levels above goal are not being prescribed a change in therapy or are actually having their therapy decreased, 4 5 despite several therapeutic guidelines for managing hyperglycemia. [6] [7] [8] One factor that has been cited for driving this lack of therapy intensification is 'clinical inertia', defined as a clinician recognizing a problem but failing to act. 9 10 Delays in treatment intensification lead not only to long (>12 months) periods of hyperglycemia, but also to a lower likelihood of therapeutic success once therapy is intensified. [11] [12] [13] [14] [15] [16] However, analyses of administrative data that identify clinical inertia when the HbA1c exceeds a guideline-level recommendation may not adequately account for mitigating factors that affect clinician decision-making. Indeed, current guidelines suggest that patient characteristics such as older age, frailty, or multiple comorbidities may be legitimate reasons for delaying therapy intensification. 3 17 18 In addition, clinician beliefs about the importance of glycemic control, especially in the context of these patient characteristics, may help explain why apparent clinical inertia is, in fact, clinical decisiveness. Therefore, to better understand the reasons why providers do and
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do not take action when their patients are not at glycemic goal, we conducted a study that taps into an often overlooked source of information-the providers themselves -and linked their responses to actual patient data extracted from electronic medical records. 
METHODS

Overall study design
The study was executed in three phases. In the first phase, we conducted 45 min qualitative interviews with 12 PCPs. Guided by the interview findings, we developed a questionnaire that was fielded to all KPNW PCPs ( phase 2). In phase 3, we linked the electronic medical records of patients with diabetes to the panels of PCPs who responded to the questionnaire to ascertain individual patient and overall panel glycemic control.
Phase 1: Qualitative interviews
We created lists of PCPs who had 'high', 'medium', and 'low' performance based on the proportion of patients with diabetes with HbA1c levels <7%, proportion of patients with diabetes with HbA1c levels >7% who were on diabetes medications, and the mean time to diabetes medication initiation after an HbA1c level >7%. We randomly approached by email PCPs from each of the three groups on the list, inviting them to participate in the structured, open-ended interview about their approach to diabetes therapy and glycemic control. Recruitment continued until we met our goal of 12 interviews, 4 from each group. A trained qualitative interviewer ( JLS) conducted the interviews using a guide developed by the research team. Interview data were analyzed by JLS using a content analysis approach [19] [20] [21] During recruitment, conducting, and analysis, both the interviewer and the participant remained unaware as to the group from which the PCP was drawn.
On the basis of data from the qualitative interviews (online supplementary table S1), we developed a short survey that could be completed in 5-10 min. Survey questions focused on glycemic goals, barriers to achieving those goals, triggers for intensification of pharmacological therapy, and opinions about goal HbA1c levels and diabetes therapy.
Phase 2: Survey of providers We sent email invitations to 252 KPNW primary care clinicians to participate in the survey (online supplementary figure S1 ) and received 124 responses. After no response to three email reminders, we sent paper copies of the survey via interoffice mail and obtained 57 additional responses, an overall response rate of 72% (n=181). Of the 181 respondents, 14 returned blank surveys and 18 did not provide their clinician identifiers (necessary for linking purposes) or had fewer than 20 general patients and/or 3 patients with diabetes on their panel, leaving 149 analyzable and linkable respondents (59% of the total survey sample).
Phase 3: Linkage to patient-level data
We identified all patients who were on PCP panels and were known to have diabetes at the time of the survey distribution (August 2013). We collected the patient HbA1c value closest to this date.
Statistical analyses
Descriptive statistics were summarized by mean and SD values and by numbers and percentages. We categorized patients' mean HbA1c values according to commonly used cut-points (<7%, 7-7.9%, ≥8%). We calculated the percentage of each PCP's panel of patients with diabetes that was within these cut-points.We also averaged together the HbA1c values of the PCP's panel of patients with diabetes. For specific questions, we first identified the number of PCPs who answered those questions in a particular way; then, among those PCPs who answered in that way, we reported the mean HbA1c values of their patients and/or the mean percentage of their patients who had HbA1c values within the following cut-points: <7%, 7-7.9%, or ≥8%. We used hierarchical generalized linear models to assess providers' beliefs about diabetic treatment and HbA1c goals as predictors of their patient's HbA1c levels. All models were adjusted by their panel's age and gender characteristics and were the level-1 variables in the models (online supplementary material: Summary of an HGLM model). The PCP's responses to the survey questions were used as level-2 variables in the models. Analyses were conducted using SAS V.9.2 (SAS institute, Cary, North Carolina, USA) and HLM 7 for Windows (Scientific Software International, Inc., Lincolnwood, Illinois, USA).
RESULTS
Baseline characteristics
In phase 1, 12 PCPs were interviewed; 252 were sent surveys during phase 2, and 149 were analyzed in phase 3 (table 1). The PCPs in each phase had generally similar demographics: the average age was 44 in phase 1 and 47 in phases 2 and 3, and 42%, 46%, and 50% were male, respectively. There was a higher percentage of internal medicine physicians among those surveyed in phase 1 and a lower number of patients with diabetes per provider in the entire survey population ( phase 2) compared with the phase 1 or phase 3 providers.
Phase 1: Qualitative interviews of 12 providers
From the qualitative interviews, we identified several themes related to diabetes treatment: patient-level barriers to optimal control, care-setting barriers to optimal control, patient factors that influence glycemic goals, facilitators to optimal control, and follow-up and outreach approach with patients at different HbA1c levels (online supplementary table S1).
Phase 2: Survey of providers
The complete survey and response frequencies are shown in online supplementary table S2. The three primary domains captured in the survey are described below.
Barriers to optimal glycemic control: The most commonly identified patient-related barriers (the majority of PCPs stated that the factor contributed ≥50% of the time) were psychosocial issues, resistance to lifestyle change, and non-compliance; the most common caresetting issue was lack of provider time to care for complex patients. The moderately common factors (>1/3 providers stated that the factor contributed ≥50% of the time) were patients' unwillingness to use insulin and competing organizational demands on providers. The least common factors (<1/3 providers stated that the factor contributed ≥50% of the time) included costs of treatment, cultural issues, other medical issues that took precedence, and a limited formulary.
Issues that delay pharmacological intensification: The most common factors (≥25% of the time) were resistance to lifestyle change and non-compliance. Unwillingness to consider insulin and psychosocial issues were less common factors (≥15 to <25% of the time), as were older age and other medical problems that took precedence (≥10 to <15% of the time). Side effects of medicines, costs of medicines, cultural issues, and a lack of established patientprovider relationship contributed only a small amount of the time (≥5 to <10% of the time).
Opinions about diabetes treatment: 80% of PCPs stated that they allowed patients who were above their individualized glycemic goal to work on lifestyle changes for 3-6 months before prescribing a pharmacological change; only 4% stated that they waited >6 months before making a pharmacological change. Eighty per cent of PCPs agreed that older patients need less stringent HbA1c goals. Almost all PCPs agreed that weight loss was a critical component of diabetes care, but only 40% agreed that the manner in which a diabetes medication affects weight influenced their therapy decisions.
Phase 3: linking PCP responses to patient level data Glycemic goals: Table 2 shows the number and percentage of responding PCPs who reported that none or very few (<10%), some (10-40%), about half (41-60%), most (61-90%), or nearly all (>90%) of their patients had HbA1c goals of <7% or 7-7.9%. Also displayed is the percentage of PCPs' panels with actual HbA1c levels of <7% and 7-7.9%. For example, 61 (42%) providers reported that most of their patients had an HbA1c goal <7%. Among those 61 providers, a mean of 56% (±0.07%) of their panel had HbA1c levels <7%. The percentage of providers' patients who were <7% or 7-7.9% was similar among providers despite different individualized glycemic goals in their respective panels of patients.
HbA1c triggers for intensification: For their patients who were already on one oral hypoglycemic agent, 45 (33%) providers reported that their trigger for a medication change was one HbA1c test result at least 0.5% above goal (table 3) . The mean HbA1c of the patients of these 45 PCPs was 7.2% (±0.2%), and on average 55.6% (±0.07%) of their panels had HbA1c values <7%. Based on the results of the hierarchical linear models, there was no statistically significant association between the HbA1c trigger and the odds of patients achieving glycemic goals. As an illustration, 13 (9%) providers reported that they would make a medication change when two HbA1c values were at least 1% above goal. The glycemia of the patients of these 13 PCPs (mean HbA1c 7.3% (±0.3%) with a mean of 53.7% (±0.06%) having HbA1c values (<7%)) was similar to the 45 PCPs whose medication trigger was more stringent.
Opinions about diabetes treatment: Table 4 shows the proportion of respondents who agreed or strongly agreed with four statements about HbA1c levels, and the proportion that disagreed or strongly disagreed with a fifth statement. Also shown is the mean HbA1c of the patients of these PCPs, the percentage of their patients with different HbA1c levels, and the age-adjusted and sex-adjusted probability of their patients attaining HbA1c <7% compared with patients of PCPs neutral for that statement. For example, 77% of providers agreed or strongly agreed that most patients should strive for HbA1c <7%. The mean HbA1c of their patients was 7.3% (±0.3%), and on average 55.3% (±0.07%) had HbA1c values <7%. However, the probability of patients of these PCPs attaining an HBA1c of <7% was not statistically different from patients of PCPs who were neutral about this statement (OR 0.94, 95% CI 0.80 to 1.11). Two statements were associated with the probability of patients attaining an HbA1c <7%. The 21% of PCPs who agreed that "current research did not support A1C levels <7%" were less likely to have patients with HbA1c levels <7% compared with PCPs who were neutral about that statement (0.87, 0.78 to 0.97; p=0.02). Second, 21% of providers disagreed that "some patients will have an A1C >9% no matter what I do." The odds of these providers' patients having an HbA1c <7% were 1.16 times (1.03 to 1.30; p=0.01) greater than the odds of patients whose providers were neutral about that statement. No other associations were statistically significant (table 4) .
DISCUSSION
This novel study examined clinician-reported attitudes and beliefs about glycemic control, barriers to achieving it, and antihyperglycemic treatment intensification practices. Importantly, it also examined the association between these beliefs and actual HbA1c results of the patients with diabetes on the responding PCPs' panels. The Diabetes Attitudes, Wishes and Needs Study (DAWN) as well as DAWN2 simultaneously collected survey data from patients with diabetes and from providers. 22 23 Although patients and providers gave parallel responses to many study topics, the studies did not attempt to link patient responses directly to their own providers. To the best of our knowledge, no previous research has linked what clinicians identify as patient and care setting barriers to the documented glycemic control of their patients.
We did not find an association between patient glycemic levels and provider-reported glycemic goals or intensification behavior. Even providers' beliefs about diabetic treatment and HbA1c goals had limited associations with the HbA1c levels of their patients. These data suggest that patient and system barriers play a larger role than clinician beliefs and behaviors in prolonged poor control and delayed treatment intensification. HbA1c levels were consistent across patients despite differences in their providers' treatment behaviors, HbA1c goals, and diabetic treatment opinions.
Our interviews and surveys revealed that providers identified patient resistance to lifestyle behaviors and taking insulin, lack of medication adherence, and psychosocial issues as barriers to optimal glycemic control, as well as lack of time to care for complex patients. These findings are consistent with concepts revealed by the DAWN study and with the notion that patients with diabetes may need greater encounter frequency or appointment length to deal with competing healthcare needs. [24] [25] [26] Also, although most providers believed weight loss to be a critical component of diabetes management, most did not take into account how diabetes medications impacted patients' weight, which may contribute to the effectiveness of pharmacological therapy. 27 This finding may have resulted from our health system's limited formulary. Alternatively, the development of new classes of medications that have more favorable effects on weight may be too recent to have changed the providers' approach to diabetes management. Regardless, despite differences in beliefs and intensification behaviors, HbA1c levels were consistent across providers. Taken together, it seems that intervention to reduce barriers to glycemic control directed at providers would not produce much benefit, and that addressing these barriers may be most fruitful at the health system level.
A unique strength of our study was the ability to assess clinician beliefs and then to link those beliefs to their patients' glycemic control. We achieved a relatively high response rate given the busy schedules of PCPs.
Our study had several limitations. Our analyses were hindered by a lack of variation in provider attitudes. This may be the result of conducting the study within a single organization that is highly structured and has a culture of conformity among the clinicians. Regardless of the setting, however, there may be little variation in attitudes and beliefs about glycemic control among PCPs in general. Our patient population lacked cultural diversity (>85% were Caucasian, non-Hispanic), which may have falsely lowered the importance of cultural issues. Indeed, in the qualitative interviews, cultural issues were often mentioned among PCPs with more diverse panels. We studied an insured population that may not represent uninsured patients or clinicians who treat them. Importantly, our restricted formulary discourages the use of newer medications that are typically more expensive than long-existing agents. This could affect the relative importance of cost issues in prescribing and intensification practices, and may also constrain our ability to assess the value of more therapeutic options. Lastly, we did not assess patient beliefs about glycemic control or attitudes about treatment intensification. Since treatment decisions are often jointly made by clinicians and their patients, our data cannot fully capture that interaction. Future work should also survey patients as patient beliefs could inform decisions about what system level programs can best improve diabetes management.
CONCLUSION
Clinicians' beliefs about glycemic goals and intensification behavior were not clearly associated with their patients' glycemia levels. Nevertheless, our findings highlighted several key factors that providers identified as driving suboptimal glycemic control including patients' resistance to lifestyle change and starting insulin, noncompliance, and psychosocial issues. It is not surprising, therefore, that providers also identified that lack of time to deal with these complex patients and their multiple issues were key reasons for prolonged suboptimal control. In the seminal paper defining clinical inertia, the authors concluded that modifying medical education to better prepare clinicians to improve management of patients with problems such as diabetes is necessary to reduce clinical inertia. 9 Given the lack of association of patients' glycemia with their providers' beliefs or behaviors, our results suggest that tackling these barriers may be best done at the system level.
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